{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:14:30Z","timestamp":1776377670556,"version":"3.51.2"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07066-1","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T11:20:31Z","timestamp":1764933631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A review of recent studies on CRISPR\/Cas9-mediated genome editing in a variety of muscle-related genetic disorders"],"prefix":"10.1186","volume":"23","author":[{"given":"Guangchao","family":"Lyu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weian","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"6","key":"7066_CR1","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00277-023-05457-2","volume":"103","author":"AM Alayoubi","year":"2024","unstructured":"Alayoubi AM, et al. CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia. Ann Hematol. 2024;103(6):1805\u201317.","journal-title":"Ann Hematol"},{"key":"7066_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-981-99-8529-6_3","volume-title":"Gene editing in plants: CRISPR-cas and its applications","author":"E Chaudhary","year":"2024","unstructured":"Chaudhary E, et al. Different Classes of CRISPR-Cas Systems. In: Gene editing in plants: CRISPR-cas and its applications. Springer; 2024. p. 73\u201394."},{"key":"7066_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12934-020-01431-z","volume":"19","author":"Z Liu","year":"2020","unstructured":"Liu Z, et al. Application of different types of CRISPR\/Cas-based systems in bacteria. Microb Cell Fact. 2020;19:1\u201314.","journal-title":"Microb Cell Fact"},{"key":"7066_CR4","doi-asserted-by":"publisher","first-page":"124054","DOI":"10.1016\/j.ijbiomac.2023.124054","volume":"238","author":"S Bhatia","year":"2023","unstructured":"Bhatia S, Yadav SK. CRISPR-Cas for genome editing: classification, mechanism, designing and applications. Int J Biol Macromol. 2023;238:124054.","journal-title":"Int J Biol Macromol"},{"key":"7066_CR5","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu Y, Li Z. CRISPR-Cas systems: overview, innovations and applications in human disease research and gene therapy. Comput Struct Biotechnol J. 2020;18:2401\u201315.","journal-title":"Comput Struct Biotechnol J"},{"issue":"10","key":"7066_CR6","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.7150\/thno.43360","volume":"10","author":"S-S Wu","year":"2020","unstructured":"Wu S-S, et al. Advances in CRISPR\/Cas-based gene therapy in human genetic diseases. Theranostics. 2020;10(10):4374.","journal-title":"Theranostics"},{"issue":"8","key":"7066_CR7","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1007\/s12015-023-10585-3","volume":"19","author":"M Lotfi","year":"2023","unstructured":"Lotfi M, et al. Recent advances in CRISPR\/Cas9 delivery approaches for therapeutic gene editing of stem cells. Stem Cell Rev Rep. 2023;19(8):2576\u201396.","journal-title":"Stem Cell Rev Rep"},{"key":"7066_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.638983","volume":"12","author":"Q Xia","year":"2021","unstructured":"Xia Q, et al. The role of autophagy in skeletal muscle diseases. Front Physiol. 2021;12:638983.","journal-title":"Front Physiol"},{"key":"7066_CR9","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/B978-0-443-10513-5.00037-1","volume-title":"Volpe\u2019s neurology of the newborn","author":"BT Darras","year":"2025","unstructured":"Darras BT, Volpe JJ. Muscle involvement and restricted disorders. In: Volpe\u2019s neurology of the newborn. UK: Elsevier; 2025. p. 1074- 1121.e18."},{"issue":"22","key":"7066_CR10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004840117","volume":"118","author":"EN Olson","year":"2021","unstructured":"Olson EN. Toward the correction of muscular dystrophy by gene editing. Proc Natl Acad Sci U S A. 2021;118(22):e2004840117.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"7066_CR11","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1172\/JCI136873","volume":"130","author":"F Chemello","year":"2020","unstructured":"Chemello F, Bassel-Duby R, Olson EN. Correction of muscular dystrophies by CRISPR gene editing. J Clin Invest. 2020;130(6):2766\u201376.","journal-title":"J Clin Invest"},{"issue":"8","key":"7066_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay6812","volume":"6","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, et al. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system. Sci Adv. 2020;6(8):eaay6812.","journal-title":"Sci Adv"},{"key":"7066_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.omtn.2022.03.004","volume":"28","author":"DR Karri","year":"2022","unstructured":"Karri DR, et al. Long-term maintenance of dystrophin expression and resistance to injury of skeletal muscle in gene edited DMD mice. Mol Ther-Nucleic Acids. 2022;28:154\u201367.","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"10","key":"7066_CR14","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1016\/j.stemcr.2021.08.011","volume":"16","author":"L He","year":"2021","unstructured":"He L, et al. CRISPR\/Cas9\/AAV9-mediated in vivo editing identifies MYC regulation of 3D genome in skeletal muscle stem cell. Stem Cell Reports. 2021;16(10):2442\u201358.","journal-title":"Stem Cell Reports"},{"issue":"1","key":"7066_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s44149-023-00065-z","volume":"3","author":"FB Balcha","year":"2023","unstructured":"Balcha FB, Neja SA. CRISPR-Cas9 mediated phage therapy as an alternative to antibiotics. Anim Dis. 2023;3(1):4.","journal-title":"Anim Dis"},{"key":"7066_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120375","volume":"294","author":"N Sayed","year":"2022","unstructured":"Sayed N, et al. Gene therapy: comprehensive overview and therapeutic applications. Life Sci. 2022;294:120375.","journal-title":"Life Sci"},{"key":"7066_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.619710","volume":"12","author":"A Khodabukus","year":"2021","unstructured":"Khodabukus A. Tissue-engineered skeletal muscle models to study muscle function, plasticity, and disease. Front Physiol. 2021;12:619710.","journal-title":"Front Physiol"},{"issue":"11","key":"7066_CR18","volume":"16","author":"JV Cardoza","year":"2024","unstructured":"Cardoza JV, et al. The role of nanoparticles in accelerating tissue recovery and inflammation control in physiotherapy practices. Cureus. 2024;16(11):e73540.","journal-title":"Cureus"},{"key":"7066_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120908","volume":"275","author":"Z Jiang","year":"2021","unstructured":"Jiang Z, et al. Genetically modified cell sheets in regenerative medicine and tissue engineering. Biomaterials. 2021;275:120908.","journal-title":"Biomaterials"},{"key":"7066_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-3-031-55653-1_6","volume-title":"Drug delivery systems for musculoskeletal tissues","author":"M Naito","year":"2024","unstructured":"Naito M, Hori M. Drug delivery systems for muscles. In: Drug delivery systems for musculoskeletal tissues. Springer; 2024. p. 189\u2013208."},{"key":"7066_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.omtm.2019.09.001","volume":"15","author":"K Piekarowicz","year":"2019","unstructured":"Piekarowicz K, et al. A muscle hybrid promoter as a novel tool for gene therapy. Mol Ther-Methods Clin Dev. 2019;15:157\u201369.","journal-title":"Mol Ther-Methods Clin Dev"},{"issue":"s2","key":"7066_CR22","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.3233\/JND-210678","volume":"8","author":"N Elangkovan","year":"2021","unstructured":"Elangkovan N, Dickson G. Gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8(s2):S303\u201316.","journal-title":"J Neuromuscul Dis"},{"issue":"15","key":"7066_CR23","doi-asserted-by":"publisher","first-page":"e1540","DOI":"10.1212\/WNL.0000000000201626","volume":"100","author":"F Muntoni","year":"2023","unstructured":"Muntoni F, et al. DMD genotypes and motor function in Duchenne muscular dystrophy: a multi-institution meta-analysis with implications for clinical trials. Neurology. 2023;100(15):e1540\u201354.","journal-title":"Neurology"},{"issue":"8","key":"7066_CR24","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1007\/s12035-023-03868-w","volume":"61","author":"AM Elasbali","year":"2024","unstructured":"Elasbali AM, et al. Discovering promising biomarkers and therapeutic targets for Duchenne muscular dystrophy: a multiomics meta-analysis approach. Mol Neurobiol. 2024;61(8):5117\u201328.","journal-title":"Mol Neurobiol"},{"issue":"4","key":"7066_CR25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ppul.25055","volume":"56","author":"NJ Abreu","year":"2021","unstructured":"Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol. 2021;56(4):710\u201320.","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"7066_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/dmcn.14365","volume":"62","author":"KG Claeys","year":"2020","unstructured":"Claeys KG. Congenital myopathies: an update. Dev Med Child Neurol. 2020;62(3):297\u2013302.","journal-title":"Dev Med Child Neurol"},{"key":"7066_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102330","volume":"68","author":"I Marty","year":"2023","unstructured":"Marty I, et al. Gene therapies for RyR1-related myopathies. Curr Opin Pharmacol. 2023;68:102330.","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"7066_CR28","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","volume":"22","author":"PB Shieh","year":"2023","unstructured":"Shieh PB, et al. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial. Lancet Neurol. 2023;22(12):1125\u201339.","journal-title":"Lancet Neurol"},{"issue":"4","key":"7066_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10040258","volume":"10","author":"L Buscara","year":"2020","unstructured":"Buscara L, Gross D-A, Daniele N. Of rAAV and men: from genetic neuromuscular disorder efficacy and toxicity preclinical studies to clinical trials and back. J Pers Med. 2020;10(4):258.","journal-title":"J Pers Med"},{"issue":"11","key":"7066_CR30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2017.126","volume":"13","author":"CE Nelson","year":"2017","unstructured":"Nelson CE, Robinson-Hamm JN, Gersbach CA. Genome engineering: a new approach to gene therapy for neuromuscular disorders. Nat Rev Neurol. 2017;13(11):647\u201361.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"7066_CR31","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3390\/genes15111489","volume":"15","author":"J Leckie","year":"2024","unstructured":"Leckie J, Zia A, Yokota T. An updated analysis of exon-skipping applicability for Duchenne muscular dystrophy using the UMD-DMD database. Genes. 2024;15(11):1489.","journal-title":"Genes"},{"key":"7066_CR32","unstructured":"Bizot F. Optimization of exon skipping therapy for the treatment of Duchenne muscular dystrophy. Universit\u00e9 Paris-Saclay; 2023"},{"issue":"4","key":"7066_CR33","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/ajmg.a.38418","volume":"176","author":"JJ Dowling","year":"2018","unstructured":"Dowling JJ, et al. Treating pediatric neuromuscular disorders: the future is now. Am J Med Genet A. 2018;176(4):804\u201341.","journal-title":"Am J Med Genet A"},{"issue":"3","key":"7066_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/jpc.16340","volume":"59","author":"D Yang","year":"2023","unstructured":"Yang D, Ruan Y, Chen Y. Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: a systematic review and meta-analysis. J Paediatr Child Health. 2023;59(3):431\u20138.","journal-title":"J Paediatr Child Health"},{"issue":"3","key":"7066_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JND-221560","volume":"10","author":"RS Finkel","year":"2023","unstructured":"Finkel RS, et al. Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: phase i ascending-dose study (STRONG). J Neuromuscul Dis. 2023;10(3):389\u2013404.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"7066_CR36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s00018-024-05229-9","volume":"81","author":"AA Zambon","year":"2024","unstructured":"Zambon AA, et al. Molecular mechanisms and therapeutic strategies for neuromuscular diseases. Cell Mol Life Sci. 2024;81(1):198.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"7066_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-012857","volume":"14","author":"AP Lieberman","year":"2019","unstructured":"Lieberman AP, Shakkottai VG, Albin RL. Polyglutamine repeats in neurodegenerative diseases. Annu Rev Pathol Mech Dis. 2019;14(1):1\u201327.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"R1","key":"7066_CR38","doi-asserted-by":"publisher","first-page":"R55","DOI":"10.1093\/hmg\/ddz131","volume":"28","author":"B Ravi","year":"2019","unstructured":"Ravi B, et al. Genetic approaches to the treatment of inherited neuromuscular diseases. Hum Mol Genet. 2019;28(R1):R55\u201364.","journal-title":"Hum Mol Genet"},{"key":"7066_CR39","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00401-020-02150-w","volume":"139","author":"A Kushnir","year":"2020","unstructured":"Kushnir A, et al. Intracellular calcium leak as a therapeutic target for RYR1-related myopathies. Acta Neuropathol. 2020;139:1089\u2013104.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"7066_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41587-019-0103-5","volume":"37","author":"D Jones","year":"2019","unstructured":"Jones D. Duchenne muscular dystrophy awaits gene therapy. Nat Biotechnol. 2019;37(4):335\u20138.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"7066_CR41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11248-021-00278-3","volume":"30","author":"M Zaynitdinova","year":"2021","unstructured":"Zaynitdinova M, Lavrov A, Smirnikhina S. Animal models for researching approaches to therapy of Duchenne muscular dystrophy. Transgenic Res. 2021;30(6):709\u201325.","journal-title":"Transgenic Res"},{"issue":"2","key":"7066_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.gendis.2023.03.017","volume":"11","author":"H Jiang","year":"2024","unstructured":"Jiang H, et al. CRISPR\/Cas9 system and its applications in nervous system diseases. Genes Dis. 2024;11(2):675\u201386.","journal-title":"Genes Dis"},{"issue":"1","key":"7066_CR43","doi-asserted-by":"publisher","first-page":"20469","DOI":"10.1038\/s41598-024-71540-x","volume":"14","author":"S Gr\u00fcttner","year":"2024","unstructured":"Gr\u00fcttner S, Kempken F. A user-friendly CRISPR\/Cas9 system for mutagenesis of Neurospora crassa. Sci Rep. 2024;14(1):20469.","journal-title":"Sci Rep"},{"key":"7066_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2024.148733","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Delivery of CRISPR\/Cas9 system by AAV as vectors for gene therapy. Gene. 2024. https:\/\/doi.org\/10.1016\/j.gene.2024.148733.","journal-title":"Gene"},{"key":"7066_CR45","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.55780","volume":"9","author":"G Cruz-Becerra","year":"2020","unstructured":"Cruz-Becerra G, Kadonaga JT. Enhancement of homology-directed repair with chromatin donor templates in cells. Elife. 2020;9:e55780.","journal-title":"Elife"},{"key":"7066_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-020-00496-y","volume":"10","author":"X Han","year":"2020","unstructured":"Han X, et al. Enhancing the antibacterial activities of sow milk via site-specific knock-in of a lactoferrin gene in pigs using CRISPR\/Cas9 technology. Cell Biosci. 2020;10:1\u20136.","journal-title":"Cell Biosci"},{"issue":"1","key":"7066_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.gendis.2023.02.027","volume":"11","author":"M Khoshandam","year":"2024","unstructured":"Khoshandam M, et al. Clinical applications of the CRISPR\/Cas9 genome-editing system: delivery options and challenges in precision medicine. Genes Dis. 2024;11(1):268\u201382.","journal-title":"Genes Dis"},{"issue":"19","key":"7066_CR48","doi-asserted-by":"publisher","first-page":"2207512","DOI":"10.1002\/advs.202207512","volume":"10","author":"DK Sahel","year":"2023","unstructured":"Sahel DK, et al. CRISPR\/Cas9 genome editing for tissue-specific in vivo targeting: nanomaterials and translational perspective. Adv Sci. 2023;10(19):2207512.","journal-title":"Adv Sci"},{"issue":"2","key":"7066_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41579-019-0299-x","volume":"18","author":"KS Makarova","year":"2020","unstructured":"Makarova KS, et al. Evolutionary classification of CRISPR\u2013Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol. 2020;18(2):67\u201383.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"7066_CR50","doi-asserted-by":"publisher","first-page":"1800085","DOI":"10.1002\/adtp.201800085","volume":"2","author":"V Carboni","year":"2019","unstructured":"Carboni V, et al. Synthetic vehicles for encapsulation and delivery of CRISPR\/Cas9 gene editing machinery. Adv Ther. 2019;2(4):1800085.","journal-title":"Adv Ther"},{"issue":"5","key":"7066_CR51","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1158\/1535-7163.MCT-17-0758","volume":"17","author":"N Floc'h","year":"2018","unstructured":"Floc\u2019h N, et al. Antitumor activity of Osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions. Mol Cancer Ther. 2018;17(5):885\u201396.","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"7066_CR52","doi-asserted-by":"publisher","first-page":"36331","DOI":"10.18632\/oncotarget.16752","volume":"8","author":"MY Park","year":"2017","unstructured":"Park MY, et al. Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR\/Cas9-mediated genome editing. Oncotarget. 2017;8(22):36331\u20138.","journal-title":"Oncotarget"},{"issue":"1","key":"7066_CR53","doi-asserted-by":"publisher","first-page":"10636","DOI":"10.1038\/s41598-024-61167-3","volume":"14","author":"JJ-Y Lim","year":"2024","unstructured":"Lim JJ-Y, et al. Generating an organ-deficient animal model using a multi-targeted CRISPR-Cas9 system. Sci Rep. 2024;14(1):10636.","journal-title":"Sci Rep"},{"issue":"2","key":"7066_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.clon.2019.09.057","volume":"32","author":"J Stewart","year":"2020","unstructured":"Stewart J, et al. Modelling the cancer phenotype in the era of CRISPR-Cas9 gene editing. Clin Oncol. 2020;32(2):69\u201374.","journal-title":"Clin Oncol"},{"issue":"8","key":"7066_CR55","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/17425247.2022.2100342","volume":"19","author":"W Yang","year":"2022","unstructured":"Yang W, et al. Progress of delivery methods for CRISPR-Cas9. Expert Opin Drug Deliv. 2022;19(8):913\u201326.","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"7066_CR56","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/14712598.2018.1536119","volume":"18","author":"Z Romero","year":"2018","unstructured":"Romero Z, DeWitt M, Walters MC. Promise of gene therapy to treat sickle cell disease. Expert Opin Biol Ther. 2018;18(11):1123\u201336.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"7066_CR57","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/biom10060839","volume":"10","author":"BH Yip","year":"2020","unstructured":"Yip BH. Recent advances in CRISPR\/Cas9 delivery strategies. Biomolecules. 2020;10(6):839.","journal-title":"Biomolecules"},{"issue":"13","key":"7066_CR58","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1016\/j.cell.2024.04.031","volume":"187","author":"AR Eggers","year":"2024","unstructured":"Eggers AR, et al. Rapid DNA unwinding accelerates genome editing by engineered CRISPR-Cas9. Cell. 2024;187(13):3249-3261.e14.","journal-title":"Cell"},{"issue":"1","key":"7066_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12985-024-02286-1","volume":"21","author":"M Hadi","year":"2024","unstructured":"Hadi M, et al. Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma. Virol J. 2024;21(1):17.","journal-title":"Virol J"},{"key":"7066_CR60","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00439-018-1933-9","volume":"137","author":"B Cai","year":"2018","unstructured":"Cai B, et al. Application of CRISPR\/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases. Hum Genet. 2018;137:679\u201388.","journal-title":"Hum Genet"},{"key":"7066_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2020.100895","volume":"34","author":"H Rahimi","year":"2020","unstructured":"Rahimi H, et al. Harnessing nanoparticles for the efficient delivery of the CRISPR\/Cas9 system. Nano Today. 2020;34:100895.","journal-title":"Nano Today"},{"issue":"5","key":"7066_CR62","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s12015-022-10345-9","volume":"18","author":"MA Widjaya","year":"2022","unstructured":"Widjaya MA, Ju JC, Lee SD. CRISPR-edited stem cell transplantation for HIV-related gene modification in vivo: a systematic review. Stem Cell Rev Rep. 2022;18(5):1743\u201355.","journal-title":"Stem Cell Rev Rep"},{"key":"7066_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114207","volume":"196","author":"J Walther","year":"2024","unstructured":"Walther J, et al. Comparative analysis of lipid nanoparticle-mediated delivery of CRISPR-Cas9 RNP versus mRNA\/sgRNA for gene editing in vitro and in vivo. Eur J Pharm Biopharm. 2024;196:114207.","journal-title":"Eur J Pharm Biopharm"},{"key":"7066_CR64","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jconrel.2024.08.019","volume":"374","author":"K Wu","year":"2024","unstructured":"Wu K, et al. Enhanced delivery of CRISPR\/Cas9 system based on biomimetic nanoparticles for hepatitis B virus therapy. J Control Rel. 2024;374:293\u2013311.","journal-title":"J Control Rel"},{"key":"7066_CR65","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.omtn.2021.11.024","volume":"27","author":"B Cardinali","year":"2022","unstructured":"Cardinali B, et al. Time-controlled and muscle-specific CRISPR\/Cas9-mediated deletion of CTG-repeat expansion in the DMPK gene. Mol Ther-Nucleic Acids. 2022;27:184\u201399.","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"5","key":"7066_CR66","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.stemcr.2020.03.026","volume":"14","author":"JB Kwon","year":"2020","unstructured":"Kwon JB, et al. Myogenic progenitor cell lineage specification by CRISPR\/Cas9-based transcriptional activators. Stem Cell Rep. 2020;14(5):755\u201369.","journal-title":"Stem Cell Rep"},{"issue":"6","key":"7066_CR67","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrcardio.2017.51","volume":"14","author":"S Von Haehling","year":"2017","unstructured":"Von Haehling S, et al. Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol. 2017;14(6):323\u201341.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"7066_CR68","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12964-022-01017-9","volume":"21","author":"E Oveili","year":"2023","unstructured":"Oveili E, et al. The potential use of mesenchymal stem cells-derived exosomes as microRNAs delivery systems in different diseases. Cell Commun Signal. 2023;21(1):20.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"7066_CR69","doi-asserted-by":"publisher","first-page":"15201","DOI":"10.1038\/ncomms15201","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, et al. Mir-29b contributes to multiple types of muscle atrophy. Nat Commun. 2017;8(1):15201.","journal-title":"Nat Commun"},{"issue":"5","key":"7066_CR70","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.ymthe.2020.03.005","volume":"28","author":"J Li","year":"2020","unstructured":"Li J, et al. CRISPR\/Cas9-mediated miR-29b editing as a treatment of different types of muscle atrophy in mice. Mol Ther. 2020;28(5):1359\u201372.","journal-title":"Mol Ther"},{"issue":"5","key":"7066_CR71","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/genes13050921","volume":"13","author":"Y Xiong","year":"2022","unstructured":"Xiong Y, et al. Identification of the CKM gene as a potential muscle-specific safe harbor locus in pig genome. Genes. 2022;13(5):921.","journal-title":"Genes"},{"key":"7066_CR72","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-1-0716-2301-5_16","volume-title":"Applications of genome modulation and editing","author":"P Kalds","year":"2022","unstructured":"Kalds P, et al. Generation of double-muscled sheep and goats by CRISPR\/Cas9-mediated knockout of the myostatin gene. In: Applications of genome modulation and editing. Springer; 2022. p. 295\u2013323."},{"key":"7066_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2022.842074","volume":"9","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, et al. Generation of heritable prominent double muscle buttock rabbits via novel site editing of myostatin gene using CRISPR\/Cas9 system. Front Vet Sci. 2022;9:842074.","journal-title":"Front Vet Sci"},{"key":"7066_CR74","first-page":"RP8627","volume":"12","author":"MM Chen","year":"2023","unstructured":"Chen MM, et al. A MSTNDel273C mutation with FGF5 knockout sheep by CRISPR\/Cas9 promotes skeletal muscle myofiber hyperplasia via MEK-ERK-FOSL1 axis. Elife. 2023;12:RP8627.","journal-title":"Elife"},{"issue":"2","key":"7066_CR75","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001812RR","volume":"35","author":"H Gu","year":"2021","unstructured":"Gu H, et al. Targeted overexpression of PPAR\u03b3 in skeletal muscle by random insertion and CRISPR\/Cas9 transgenic pig cloning enhances oxidative fiber formation and intramuscular fat deposition. FASEB J. 2021;35(2):e21308.","journal-title":"FASEB J"},{"issue":"1","key":"7066_CR76","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1038\/s41467-023-41769-7","volume":"14","author":"M Th\u00fcrkauf","year":"2023","unstructured":"Th\u00fcrkauf M, et al. Fast, multiplexable and efficient somatic gene deletions in adult mouse skeletal muscle fibers using AAV-CRISPR\/Cas9. Nat Commun. 2023;14(1):6116.","journal-title":"Nat Commun"},{"key":"7066_CR77","doi-asserted-by":"crossref","unstructured":"He L et al. In vivo study of key transcription factors in muscle satellite cells by CRISPR\/Cas9\/AAV9-sgRNA mediated genome editing. bioRxiv. 2019; 797746.","DOI":"10.1101\/797746"},{"issue":"1","key":"7066_CR78","doi-asserted-by":"publisher","first-page":"14454","DOI":"10.1038\/ncomms14454","volume":"8","author":"NE Bengtsson","year":"2017","unstructured":"Bengtsson NE, et al. Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun. 2017;8(1):14454.","journal-title":"Nat Commun"},{"issue":"6","key":"7066_CR79","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.032201","volume":"11","author":"T Sui","year":"2018","unstructured":"Sui T, et al. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR\/Cas9. Dis Model Mech. 2018;11(6):dmm032201.","journal-title":"Dis Model Mech"},{"issue":"2","key":"7066_CR80","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.stemcr.2021.12.003","volume":"17","author":"SA Domenig","year":"2022","unstructured":"Domenig SA, et al. CRISPR\/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy. Stem Cell Rep. 2022;17(2):321\u201336.","journal-title":"Stem Cell Rep"},{"key":"7066_CR81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.omtn.2017.02.007","volume":"7","author":"P Zhu","year":"2017","unstructured":"Zhu P, et al. CRISPR\/Cas9-mediated genome editing corrects dystrophin mutation in skeletal muscle stem cells in a mouse model of muscle dystrophy. Mol Ther-Nucleic Acids. 2017;7:31\u201341.","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"5","key":"7066_CR82","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/sctm.16-0427","volume":"6","author":"P Zhu","year":"2017","unstructured":"Zhu P, et al. Selective expansion of skeletal muscle stem cells from bulk muscle cells in soft three-dimensional fibrin gel. Stem Cells Transl Med. 2017;6(5):1412\u201323.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"7066_CR83","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/hmg\/ddab218","volume":"31","author":"A M\u00e9rien","year":"2022","unstructured":"M\u00e9rien A, et al. Crispr gene editing in pluripotent stem cells reveals the function of MBNL proteins during human in vitro myogenesis. Hum Mol Genet. 2022;31(1):41\u201356.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"7066_CR84","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1016\/j.stemcr.2021.08.011","volume":"16","author":"L He","year":"2021","unstructured":"He L, et al. CRISPR\/Cas9\/AAV9-mediated in vivo editing identifies MYC regulation of 3D genome in skeletal muscle stem cell. Stem Cell Rep. 2021;16(10):2442\u201358.","journal-title":"Stem Cell Rep"},{"issue":"1","key":"7066_CR85","first-page":"9246825","volume":"2023","author":"L Mavrommatis","year":"2023","unstructured":"Mavrommatis L, et al. CRISPR\/Cas9 genome editing in LGMD2A\/R1 patient-derived induced pluripotent stem and skeletal muscle progenitor cells. Stem Cells Int. 2023;2023(1):9246825.","journal-title":"Stem Cells Int"},{"issue":"11","key":"7066_CR86","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3390\/cells13110972","volume":"13","author":"NR Dhoke","year":"2024","unstructured":"Dhoke NR, et al. A novel CRISPR-Cas9 strategy to target DYSTROPHIN mutations downstream of exon 44 in patient-specific DMD iPSCs. Cells. 2024;13(11):972.","journal-title":"Cells"},{"issue":"1","key":"7066_CR87","doi-asserted-by":"publisher","first-page":"21238","DOI":"10.1038\/s41598-024-70075-5","volume":"14","author":"J Lemoine","year":"2024","unstructured":"Lemoine J, et al. Correction of exon 2, exon 2\u20139 and exons 8\u20139 duplications in DMD patient myogenic cells by a single CRISPR\/Cas9 system. Sci Rep. 2024;14(1):21238.","journal-title":"Sci Rep"},{"issue":"11","key":"7066_CR88","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.ymthe.2018.08.010","volume":"26","author":"BL Duch\u00eane","year":"2018","unstructured":"Duch\u00eane BL, et al. CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in vitro and in vivo. Mol Ther. 2018;26(11):2604\u201316.","journal-title":"Mol Ther"},{"issue":"11","key":"7066_CR89","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.ymthe.2021.09.003","volume":"29","author":"A Pickar-Oliver","year":"2021","unstructured":"Pickar-Oliver A, et al. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. Mol Ther. 2021;29(11):3243\u201357.","journal-title":"Mol Ther"},{"key":"7066_CR90","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.omtn.2017.10.006","volume":"9","author":"C Provenzano","year":"2017","unstructured":"Provenzano C, et al. CRISPR\/Cas9-mediated deletion of CTG expansions recovers normal phenotype in myogenic cells derived from myotonic dystrophy 1 patients. Mol Ther Nucleic Acids. 2017;9:337\u201348.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"16","key":"7066_CR91","doi-asserted-by":"publisher","first-page":"8275","DOI":"10.1093\/nar\/gky548","volume":"46","author":"S Dastidar","year":"2018","unstructured":"Dastidar S, et al. Efficient CRISPR\/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells. Nucleic Acids Res. 2018;46(16):8275\u201398.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"7066_CR92","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41434-022-00336-3","volume":"29","author":"D-N Wang","year":"2022","unstructured":"Wang D-N, et al. CRISPR\/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy. Gene Ther. 2022;29(12):730\u20137.","journal-title":"Gene Ther"},{"issue":"5","key":"7066_CR93","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s11010-023-04759-3","volume":"479","author":"F Alizadeh","year":"2024","unstructured":"Alizadeh F, et al. Production of duchenne muscular dystrophy cellular model using crispr-cas9 exon deletion strategy. Mol Cell Biochem. 2024;479(5):1027\u201340.","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"7066_CR94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206324120","volume":"120","author":"A Morin","year":"2023","unstructured":"Morin A, et al. Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle. Proc Natl Acad Sci U S A. 2023;120(2):e2206324120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7066_CR95","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40259-023-00632-3","volume":"38","author":"S Szwec","year":"2024","unstructured":"Szwec S, et al. Dystrophin-and utrophin-based therapeutic approaches for treatment of Duchenne muscular dystrophy: a comparative review. BioDrugs. 2024;38(1):95\u2013119.","journal-title":"BioDrugs"},{"key":"7066_CR96","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.omtn.2023.01.004","volume":"31","author":"J Poyatos-Garc\u00eda","year":"2023","unstructured":"Poyatos-Garc\u00eda J, et al. CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2. Mol Ther Nucleic Acids. 2023;31:324\u201338.","journal-title":"Mol Ther Nucleic Acids"},{"key":"7066_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-018-0648-4","volume":"6","author":"S Gibertini","year":"2018","unstructured":"Gibertini S, et al. Long term follow-up and further molecular and histopathological studies in the LGMD1F sporadic TNPO3-mutated patient. Acta Neuropathol Commun. 2018;6:1\u20136.","journal-title":"Acta Neuropathol Commun"},{"issue":"10","key":"7066_CR98","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100539RR","volume":"35","author":"\u00c1 Bl\u00e1zquez-Bernal","year":"2021","unstructured":"Bl\u00e1zquez-Bernal \u00c1, et al. Inhibition of autophagy rescues muscle atrophy in a LGMDD2 Drosophila model. FASEB J. 2021;35(10):e21914.","journal-title":"FASEB J"},{"issue":"3","key":"7066_CR99","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000337","volume":"5","author":"A Vihola","year":"2019","unstructured":"Vihola A, et al. Novel mutation in TNPO3 causes congenital limb-girdle myopathy with slow progression. Neurol Genet. 2019;5(3):e337.","journal-title":"Neurol Genet"},{"key":"7066_CR100","doi-asserted-by":"crossref","unstructured":"Shin JW et al. Personalized allele-specific CRISPR-Cas9 strategies for myofibrillar myopathy. 2024.","DOI":"10.1101\/2024.02.03.24302252"},{"issue":"3","key":"7066_CR101","doi-asserted-by":"publisher","first-page":"239a","DOI":"10.1016\/j.bpj.2022.11.1401","volume":"122","author":"M Beaufils","year":"2023","unstructured":"Beaufils M, et al. Gene therapy strategies using CRISPR\/Cas9 for RyR1-related myopathies. Biophys J. 2023;122(3):239a\u201340a.","journal-title":"Biophys J"},{"key":"7066_CR102","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.omtn.2019.02.019","volume":"16","author":"A Rabai","year":"2019","unstructured":"Rabai A, et al. Allele-specific CRISPR\/Cas9 correction of a heterozygous DNM2 mutation rescues centronuclear myopathy cell phenotypes. Mol Ther-Nucleic Acids. 2019;16:246\u201356.","journal-title":"Mol Ther-Nucleic Acids"},{"key":"7066_CR103","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.1016\/j.nmd.2020.08.351","volume":"30","author":"N Sabha","year":"2020","unstructured":"Sabha N, et al. Highlights across myology: O. 14 Gene editing using CRISPR\/CAS9 in an animal model of nemaline myopathy. Neuromuscul Disord. 2020;30:S150.","journal-title":"Neuromuscul Disord"},{"key":"7066_CR104","doi-asserted-by":"publisher","first-page":"104441","DOI":"10.1016\/j.nmd.2024.07.371","volume":"43","author":"C Lama","year":"2024","unstructured":"Lama C, et al. 628P Development of a CRISPR\/CasX 4q telomeric region ablation strategy for FSHD1 using an isogenic hiPSC line and a FSHD1 fibroblast cell line. Neuromuscul Disord. 2024;43:104441\u20135362.","journal-title":"Neuromuscul Disord"},{"key":"7066_CR105","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.nmd.2016.06.444","volume":"26","author":"R Cohn","year":"2016","unstructured":"Cohn R. Gene therapy 2.0: CRISPR\/Cas9 genome editing provides novel therapeutic avenues for neuromuscular disorders. Neuromuscul Disord. 2016;26:S208\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"7066_CR106","first-page":"341","volume":"34","author":"CS Young","year":"2019","unstructured":"Young CS, Pyle AD, Spencer MJ. Crispr for neuromuscular disorders: gene editing and beyond. Physiology (Bethesda). 2019;34(5):341\u201353.","journal-title":"Physiology (Bethesda)"},{"key":"7066_CR107","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.omtn.2018.10.004","volume":"13","author":"JJ Lee","year":"2018","unstructured":"Lee JJ, et al. Identification of novel antisense-mediated exon skipping targets in DYSF for therapeutic treatment of dysferlinopathy. Mol Ther-Nucleic Acids. 2018;13:596\u2013604.","journal-title":"Mol Ther-Nucleic Acids"},{"key":"7066_CR108","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99357","author":"EJ Wyatt","year":"2018","unstructured":"Wyatt EJ, et al. Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.99357.","journal-title":"JCI Insight"},{"issue":"2","key":"7066_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212198","volume":"14","author":"H Baba\u010di\u0107","year":"2019","unstructured":"Baba\u010di\u0107 H, et al. CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: a systematic review. PLoS ONE. 2019;14(2):e0212198.","journal-title":"PLoS ONE"},{"issue":"536","key":"7066_CR110","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay0271","volume":"12","author":"A Lek","year":"2020","unstructured":"Lek A, et al. Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy. Sci Transl Med. 2020;12(536):eaay0271.","journal-title":"Sci Transl Med"},{"key":"7066_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2022.937879","volume":"4","author":"V Mariot","year":"2022","unstructured":"Mariot V, Dumonceaux J. Gene editing to tackle Facioscapulohumeral muscular dystrophy. Front Genome Ed. 2022;4:937879.","journal-title":"Front Genome Ed"},{"key":"7066_CR112","doi-asserted-by":"publisher","first-page":"S190","DOI":"10.1016\/j.nmd.2016.06.376","volume":"26","author":"D Kemaladewi","year":"2016","unstructured":"Kemaladewi D, et al. CRISPR\/Cas9-mediated exon inclusion in Lama2 gene alleviates dystrophic pathology in MDC1A mouse model. Neuromuscul Disord. 2016;26:S190.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"7066_CR113","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","volume":"20","author":"DR Asher","year":"2020","unstructured":"Asher DR, et al. Clinical development on the frontier: gene therapy for duchenne muscular dystrophy. Expert Opin Biol Ther. 2020;20(3):263\u201374.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"7066_CR114","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12033-023-00724-z","volume":"66","author":"F Morshedzadeh","year":"2024","unstructured":"Morshedzadeh F, et al. An update on the application of CRISPR technology in clinical practice. Mol Biotechnol. 2024;66(2):179\u201397.","journal-title":"Mol Biotechnol"},{"issue":"10","key":"7066_CR115","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/cells13100800","volume":"13","author":"M Laurent","year":"2024","unstructured":"Laurent M, et al. CRISPR-based gene therapies: from preclinical to clinical treatments. Cells. 2024;13(10):800.","journal-title":"Cells"},{"key":"7066_CR116","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","volume":"10","author":"F Uddin","year":"2020","unstructured":"Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol. 2020;10:1387.","journal-title":"Front Oncol"},{"issue":"13","key":"7066_CR117","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek A, et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N Engl J Med. 2023;389(13):1203\u201310.","journal-title":"N Engl J Med"},{"issue":"11","key":"7066_CR118","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan D. Mini-review: lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther. 2023;31(11):3123\u20136.","journal-title":"Mol Ther"},{"issue":"4","key":"7066_CR119","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/14740338.2024.2447072","volume":"24","author":"A Tang","year":"2025","unstructured":"Tang A, Yokota T. Is duchenne gene therapy a suitable treatment despite its immunogenic class effect? Expert Opin Drug Saf. 2025;24(4):395\u2013411.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"7066_CR120","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493\u2013502.","journal-title":"N Engl J Med"},{"issue":"1","key":"7066_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-021-01487-4","volume":"21","author":"MF Rasul","year":"2022","unstructured":"Rasul MF, et al. Strategies to overcome the main challenges of the use of CRISPR\/Cas9 as a replacement for cancer therapy. Mol Cancer. 2022;21(1):1\u201330.","journal-title":"Mol Cancer"},{"issue":"11","key":"7066_CR122","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.3390\/cells9112518","volume":"9","author":"M Saifaldeen","year":"2020","unstructured":"Saifaldeen M, et al. CRISPR FokI dead Cas9 system: principles and applications in genome engineering. Cells. 2020;9(11):2518.","journal-title":"Cells"},{"issue":"9\u201310","key":"7066_CR123","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/hum.2023.053","volume":"34","author":"F Chemello","year":"2023","unstructured":"Chemello F, Olson EN, Bassel-Duby R. Crispr-editing therapy for Duchenne muscular dystrophy. Hum Gene Ther. 2023;34(9\u201310):379\u201387.","journal-title":"Hum Gene Ther"},{"issue":"19","key":"7066_CR124","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.3390\/cells11192964","volume":"11","author":"G Chen","year":"2022","unstructured":"Chen G, et al. CRISPR-based therapeutic gene editing for Duchenne muscular dystrophy: advances, challenges and perspectives. Cells. 2022;11(19):2964.","journal-title":"Cells"},{"issue":"10","key":"7066_CR125","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41551-019-0431-2","volume":"3","author":"AM Moreno","year":"2019","unstructured":"Moreno AM, et al. Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy. Nat Biomed Eng. 2019;3(10):806\u201316.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"7066_CR126","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","volume":"12","author":"CH Hakim","year":"2021","unstructured":"Hakim CH, et al. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat Commun. 2021;12(1):6769.","journal-title":"Nat Commun"},{"issue":"3","key":"7066_CR127","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3390\/ijms23031832","volume":"23","author":"E Erkut","year":"2022","unstructured":"Erkut E, Yokota T. CRISPR therapeutics for Duchenne muscular dystrophy. Int J Mol Sci. 2022;23(3):1832.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7066_CR128","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","volume":"12","author":"E Kenjo","year":"2021","unstructured":"Kenjo E, et al. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun. 2021;12(1):7101.","journal-title":"Nat Commun"},{"issue":"4","key":"7066_CR129","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/jpm8040038","volume":"8","author":"KRQ Lim","year":"2018","unstructured":"Lim KRQ, Yoon C, Yokota T. Applications of CRISPR\/Cas9 for the treatment of Duchenne muscular dystrophy. J Pers Med. 2018;8(4):38.","journal-title":"J Pers Med"},{"key":"7066_CR130","doi-asserted-by":"publisher","first-page":"1143157","DOI":"10.3389\/fbioe.2023.1143157","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo C, et al. Off-target effects in CRISPR\/Cas9 gene editing. Front Bioeng Biotechnol. 2023;11:1143157.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"7066_CR131","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41467-020-14957-y","volume":"11","author":"P Gee","year":"2020","unstructured":"Gee P, et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat Commun. 2020;11(1):1334.","journal-title":"Nat Commun"},{"key":"7066_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.833833","volume":"10","author":"L Chung Liang","year":"2022","unstructured":"Chung Liang L, Sulaiman N, Yazid MD. A decade of progress in gene targeted therapeutic strategies in Duchenne muscular dystrophy: a systematic review. Front Bioeng Biotechnol. 2022;10:833833.","journal-title":"Front Bioeng Biotechnol"},{"issue":"9\u201310","key":"7066_CR133","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1089\/hum.2023.059","volume":"34","author":"S Fatehi","year":"2023","unstructured":"Fatehi S, et al. Advances in CRISPR\/Cas9 genome editing for the treatment of muscular dystrophies. Hum Gene Ther. 2023;34(9\u201310):388\u2013403.","journal-title":"Hum Gene Ther"},{"key":"7066_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101365","author":"K Singh","year":"2024","unstructured":"Singh K, et al. Comprehensive analysis of off-target and on-target effects resulting from liver-directed CRISPR-Cas9-mediated gene targeting with AAV vectors. Mol Ther Methods Clin Dev. 2024. https:\/\/doi.org\/10.1016\/j.omtm.2024.101365.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"7066_CR135","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","volume":"25","author":"CE Nelson","year":"2019","unstructured":"Nelson CE, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019;25(3):427\u201332.","journal-title":"Nat Med"},{"issue":"15","key":"7066_CR136","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/ijms20153689","volume":"20","author":"RH Raaijmakers","year":"2019","unstructured":"Raaijmakers RH, et al. CRISPR\/Cas applications in myotonic dystrophy: expanding opportunities. Int J Mol Sci. 2019;20(15):3689.","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07066-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07066-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07066-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:05:10Z","timestamp":1764939910000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07066-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":136,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7066"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07066-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All author consent to the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1381"}}